Mirtazapina Flas Viatris (Mirtazapine)

Mirtazapine increases neurotransmission by blocking presynaptic α2‑adrenergic receptors, leading to higher norepinephrine release, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, which enhances serotonergic activity. Its additional H1‑receptor antagonism contributes to sedation and appetite stimulation.

The exact dose is individualized by the prescribing clinician based on the patient’s clinical condition, age, and response to therapy. Typically, treatment starts at a low dose and may be titrated upward, but the specific regimen should always follow the prescriber’s instructions.

Safety data for mirtazapine during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians usually discuss alternatives and closely monitor any pregnant or nursing patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs in its receptor profile. It often causes more sedation and weight gain, which can be advantageous for patients with insomnia or poor appetite, whereas SSRIs are generally more activating and have a different side‑effect spectrum.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme heat. Keep the container tightly closed and out of reach of children.

Mirtazapina Flas Viatris is taken orally, usually once daily in the evening to take advantage of its sedative effect. It may be swallowed with or without food; however, taking it with a light snack can reduce gastrointestinal discomfort for some patients.

The most serious risks include the emergence or worsening of suicidal thoughts, especially early in treatment, agranulocytosis or severe neutropenia, significant hepatic dysfunction, and rare cases of severe hypersensitivity or serotonin syndrome when combined with other serotonergic drugs.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease or a history of seizures.